Full Title

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily
Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive
Multiple Sclerosis (PPMS)

 

Further information

https://clinicaltrials.gov/ct2/show/NCT02284568?term=laquinimod+ppms&rank=1